Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesGrifols SA ADR

Grifols SA ADR

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
8.84 USD 0.00(0%)
Last update at 2026-11-11T21:00:00Z
VOLUME
724575
Market Cap
5710.03M
P/E
12.16

Momentum Score

…

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
8.60
Low
8.88
High
52 Week Price Range
6.79
Low
10.96
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Grifols SA is a global healthcare company focused on plasma-derived therapies, hospital diagnostics and a network of plasma collection centers supplying immunoglobulins, albumin and clotting factors. Long-term growth could be supported by rising demand for immunotherapies, expansion of plasma supply and geographic diversification, and investors may view its leading fractionation position and recurring-revenue products as attractive.

Material risks include regulatory and pricing pressure in plasma products, disruptions to plasma collection and leverage/refinancing exposure that could constrain financial flexibility.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.84
Dividend Yield
2.10%
Revenue TTM
7524.00M
Revenue Per Share
5.53
Gross Profit TTM
2919.32M
Debt / Equity
1.66
ROE
6.17%
Net Debt
7915.63M
ROCE
6.70%
Diluted EPS TTM
0.69

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 590.73M 444.00M 207.02M 361.26M 350.45M
Minority interest -98.00M -55.89M -114.90M -62.87M -82.52M
Net income 386.13M 156.92M 42.32M 208.28M 265.33M
Selling general administrative 1063.00M 1144.01M 1265.53M 1190.42M 1061.51M
Selling and marketing expenses - - 5.30M - -
Gross profit 2579.99M 2794.54M 2483.48M 2231.53M 1962.60M
Reconciled depreciation 450.00M 437.90M 441.92M 407.86M 359.77M
Ebit 1187.22M 1046.57M 723.08M 805.68M 595.06M
Ebitda 1619.46M 1484.46M 1169.50M 1112.03M 955.39M
Depreciation and amortization 432.24M 437.90M 446.42M 306.35M 360.32M
Operating income 1187.22M 1192.02M 782.32M 805.68M 595.06M
Other operating expenses 6039.83M 6020.37M 5809.66M 5361.77M 4370.61M
Interest expense 600.33M 773.15M 516.06M 362.63M 233.81M
Tax provision 115.00M 231.19M 27.21M 90.11M 85.13M
Interest income 34.00M 44.42M 62.33M 33.86M 11.55M
Net interest income -605.00M -701.12M -574.14M -462.67M -266.44M
Income tax expense 110.46M 231.19M 43.35M 90.11M 85.13M
Total revenue 7227.05M 7212.38M 6591.98M 6063.97M 4933.12M
Total operating expenses 1392.77M 1602.52M 1701.16M 1529.33M 1400.09M
Cost of revenue 4647.06M 4417.84M 4108.49M 3832.44M 2970.52M
Total other income expense net -596.49M -748.02M -575.30M -444.42M -244.61M
Net income from continuing ops 500.00M 212.81M 138.29M 271.15M 265.33M
Net income applicable to common shares - - - 208.28M 182.80M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 19749.59M 21405.24M 21454.67M 21533.98M 19233.83M
Intangible assets 2726.84M 2926.13M 2832.20M 2949.15M 1636.95M
Other current assets 107.95M 87.17M 1652.19M 81.81M 64.08M
Total liab 12133.83M 12798.22M 13468.38M 13076.43M 11086.80M
Total stockholder equity 5268.76M 5883.73M 5827.17M 6129.94M 6096.64M
Deferred long term liab - - - 1622.64M 633.24M
Other current liab 714.70M 508.33M 565.38M 504.82M 407.60M
Common stock 119.95M 119.60M 119.60M 1030.33M 1030.33M
Capital stock 120.00M 119.60M 119.60M 1030.33M 1030.33M
Retained earnings 300.00M 156.92M 59.31M 208.28M 182.80M
Other liab - - - 2051.73M 682.36M
Good will 6830.09M 7403.06M 6802.13M 7011.91M 6228.90M
Other assets - - - 1930.41M 882.61M
Cash 824.65M 979.78M 529.58M 547.98M 655.49M
Total current liabilities 2018.14M 2156.15M 2315.60M 1955.85M 3474.31M
Current deferred revenue 76.97M 70.86M 39.19M 37.83M 43.54M
Net debt 7915.63M 9105.84M 9587.86M 9202.15M 8668.81M
Short term debt 385.84M 639.66M 897.91M 681.27M 2394.18M
Short long term debt 410.00M 523.13M 790.81M 578.92M 2345.61M
Short long term debt total 8740.28M 10085.62M 10117.44M 9750.12M 9324.31M
Other stockholder equity 779.67M 776.28M 698.66M -162.22M -164.19M
Property plant equipment - - - 4168.49M 3343.15M
Total current assets 5071.84M 5727.54M 6451.90M 4653.59M 5510.28M
Long term investments 460.00M 528.97M 565.11M 2548.89M 2359.97M
Net tangible assets - - - -2208.48M -1135.97M
Short term investments 23.00M 21.18M 116.14M 43.26M 2029.11M
Net receivables 844.64M 1079.32M 810.86M 754.82M 495.48M
Long term debt 8074.00M 8421.11M 8215.30M 8154.26M 6104.97M
Inventory 3294.60M 3560.10M 3459.28M 3201.36M 2259.35M
Accounts payable 840.64M 852.30M 813.11M 731.92M 628.99M
Accumulated other comprehensive income 4369.14M 4830.92M 4949.58M 5053.55M 5047.70M
Non currrent assets other 15.99M 167.72M 154.39M 27.03M 2.07M
Non current assets total 14677.75M 15677.70M 15002.76M 16880.39M 13723.56M
Capital lease obligations 1082.00M 1141.38M 1111.33M 1016.94M 873.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -52.00M 886.67M -397.64M -1978.82M 9.82M
Change to liabilities - - - 80.21M 40.45M
Total cashflows from investing activities -556.15M 886.67M -394.72M -1978.82M -29.39M
Net borrowings -119.00M -111.49M -116.39M -177.37M 1878.52M
Total cash from financing activities -508.12M -1358.71M 171.49M -173.49M 1472.92M
Change to operating activities - - - -9.01M -7.08M
Net income 386.13M 444.00M 207.02M 361.26M 350.45M
Change in cash -38.85M 450.20M -19.63M -2127.63M 2095.96M
Begin period cash flow 863.49M 529.58M 549.21M 2675.61M 579.65M
End period cash flow 824.65M 979.78M 529.58M 547.98M 2675.61M
Total cash from operating activities 1005.68M 902.17M 218.69M -10.87M 596.98M
Depreciation 432.24M 437.90M 446.42M 407.86M 359.77M
Other cashflows from investing activities - 1448.93M -62.63M - -
Dividends paid 122.95M 0.96M 0.00M -0.59M -258.95M
Change to inventory -93.17M 25.82M -411.44M -600.25M -157.47M
Change to account receivables -30.74M -41.88M -68.81M -80.17M -16.81M
Sale purchase of stock -123.91M 0.00M 0.00M -3.46M -125.70M
Other cashflows from financing activities -78.76M -1246.26M 287.89M -65.16M 1940.26M
Change to netincome - - - -17.79M 195.31M
Capital expenditures 254.54M 371.37M 310.32M 375.56M 315.09M
Change in working capital -24.01M 22.38M -362.84M -609.22M -140.91M
Other non cash items 211.32M -2.10M -71.91M -170.77M 27.66M
Free cash flow 751.14M 530.80M -91.63M -386.43M 281.89M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
GRFS
Grifols SA ADR		 -
-%		 8.84 12.16 9.47 0.76 0.93 1.94 8.89
LLY
Eli Lilly and Company		 5.00
0.35%		 1437.29 38.16 24.15 12.72 29.95 13.31 25.43
JNJ
Johnson & Johnson		 -0.02
0.01%		 280.76 30.96 20.79 6.58 7.55 6.84 19.73
ABBV
AbbVie Inc		 1.09
0.37%		 294.98 74.10 16.21 7.22 50.46 8.18 27.04
RHHVF
Roche Holding AG Participation		 -6.12
1.25%		 484.80 24.16 16.53 5.71 8.88 4.94 14.76

Profile*

Grifols SA ADR

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

Parque Empresarial Can Sant Joan, Barcelona, Spain, 08174

34 935 71 22 00

https://www.grifols.com

25258

Name Title Year Born
Mr. Steven Francis Mayer J.D. Exec. Chairman 1960
Mr. Raimon Grifols Roura Co-CEO & Exec. Director 1964
Mr. Víctor Grifols Deu Co-CEO & Exec. Director 1977
Mr. Alfredo Arroyo Guerra CFO & VP 1958
Mrs. Eva Bastida Tubau Corp. VP and Director of Scientific & Medical Affairs NA
Ms. Nuria Pascual Lapeña VP of Corp. Treasury, Risk Management Investor Relation & Sustainability Officer 1964
Mr. David Ian Bell Gen. Counsel & Chief Corp. Devel. Officer 1954
Mr. Mateo Florencio Borrás Humbert Corp. VP & Chief HR Officer 1956
Ms. Maria Teresa-Rioné Llano Chief Communications Officer 1965
Ms. Montserrat Gaja Llamas Chief HR Officer 1965

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

MAL
CAD 38.85
+13.53%
SOIL
CAD 8.39
+12.02%
QNC
CAD 1.48
+10.45%
TCL-B
CAD 7.26
+9.01%
CLS
CAD 345.53
+8.41%
GSY
CAD 37.75
-16.04%
BYD
CAD 109.98
-11.99%
ELE
CAD 20.12
-11.95%
LAC
CAD 2.39
-11.15%
CFW
CAD 6.51
-10.82%

Equity Sectors*

  • Basic Materials

    -1.75%

  • Communication Services

    +0.20%

  • Consumer Cyclical

    +0.18%

  • Consumer Defensive

    +0.06%

  • Energy

    +1.65%

  • Financial Services

    +0.10%

  • Healthcare

    +1.25%

  • Industrials

    +1.60%

  • Real Estate

    -0.29%

  • Technology

    +2.72%

  • Utilities

    +0.12%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…